Drugs are commonly used in combinations larger than two for treating bacterial infection. However, it is generally impossible to infer directly from the effects of individual drugs the net effect of a multidrug combination. Here we develop a mechanism-independent method for predicting the microbial growth response to combinations of more than two drugs. Performing experiments in both Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria, we demonstrate that for a wide range of drugs, the bacterial responses to drug pairs are sufficient to infer the effects of larger drug combinations. To experimentally establish the broad applicability of the method, we use drug combinations comprising protein synthesis inhibitors (macrolides, aminoglycosides, tetracyclines, lincosamides, and chloramphenicol), DNA synthesis inhibitors (fluoroquinolones and quinolones), folic acid synthesis inhibitors (sulfonamides and diaminopyrimidines), cell wall synthesis inhibitors, polypeptide antibiotics, preservatives, and analgesics. Moreover, we show that the microbial responses to these drug combinations can be predicted using a simple formula that should be widely applicable in pharmacology. These findings offer a powerful, readily accessible method for the rational design of candidate therapies using combinations of more than two drugs. In addition, the accurate predictions of this framework raise the question of whether the multidrug response in bacteria obeys statistical, rather than chemical, laws for combinations larger than two.
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pairwise | entropy | prokaryotes | dose-response relationship C ombinations of three or more drugs have been studied in both clinical and laboratory settings as potential treatments for severe microbial infections (1) (2) (3) (4) . Drug interactions, including those that are clinically beneficial, have typically been studied using descriptive, rather than predictive, approaches that quantify the effects of a given drug pair on growth (5-7). For example, two drugs whose effects on microbial growth counteract one another, when used in combination, are known as antagonistic, whereas drugs whose potencies are significantly increased in combination are referred to as synergistic. As a result of these interactions, the effects of drug combinations cannot, in general, be predicted based on the effects of the drugs alone (7) . Although combinations of two drugs have been studied extensively, little is known about the way in which more than two drugs combine to yield higher-order effects on bacterial growth, which is the relevant clinical outcome in treatments of bacterial infections. Here, we ask if it is possible to understand and to predict the effects of these larger drug combinations without relying on specific mechanistic details but rather on principles shared by a large number of biological systems.
For example, consider a classic three-drug combination of chloramphenicol (a protein synthesis inhibitor), ofloxacin (a fluoroquinolone DNA synthesis inhibitor), and trimethoprim (a folic acid synthesis inhibitor) at the following concentrations:
[chloramphenicol]=1.5 μg/mL, [ofloxacin]=40 ng/mL, and [trimethoprim]=0.3 μg/mL. The growth rate of E. coli treated with each drug alone is about 0.58, 0.47, and 0.39 (normalized by the growth of untreated cells), respectively. Combining chloramphenicol and ofloxacin leads to a growth rate of 0.53, which is significantly higher than expected from a naive multiplication of the single drug rates (0.27) and consistent with previously observed antagonism between DNA synthesis inhibitors and protein synthesis inhibitors (8) . On the other hand, combining ofloxacin with trimethoprim completely eradicates growth (growth < 0.01, compared with 0.18 expected from single drug growth rates), consistent with previously reported synergy between trimethoprim and fluoroquinolones (9) . Finally, the combination of chloramphenicol and trimethoprim leads to a growth rate of 0.16, slightly smaller than the 0.23 predicted from single drug growth rates. The effects of all three pairs of drugs differ significantly from that predicted by multiplication of single drug effects. Therefore, there is seemingly little hope that such an assumption of independence will be useful when all three drugs are combined and the chemical complexity of the problem is increased. Surprisingly, the growth rate in the presence of all three drugs (0.11) is equal to the product of single drug growth rates, suggesting that the drugs act independently. Why have the previously strong interactions between drug pairs been eliminated when the three drugs are combined, leading to a mixture of effectively independent drugs? One hypothesis would be that the net effect of the drug combination arises from compensatory interactions that can only be measured when all three drugs are present. Alternatively, the net effect could follow directly from the accumulation of interactions between pairs of drugs. We wish to answer this question using a quantitative framework to provide insight into how the cell integrates signals from larger drug combinations.
To tackle this question for a wide range of drug combinations, we develop a mechanism-independent model to quantify the relative contributions of combined chemical exposure-that is, onedrug effects, two-drug effects, and, in general, N-drug effects-to the multidrug growth response. We construct the model using a common statistical method, entropy maximization, which ensures that the model does not incorporate unwarranted statistical structure. We then test predictions of this framework using two species that represent Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus) bacteria. This predictive framework is a potentially powerful tool for studying multidrug effects, even without knowledge of the underlying network structure, molecular dynamics, or any other intracellular details.
Results
Response of E. coli to Single Drugs and Drug Pairs. First, we measured the growth of E. coli in the presence of a single drug and then pairs of drugs by growing liquid cultures in Luria-Bertani media. We used a large variety of drugs, including several classes of protein synthesis inhibitors (with 30S and 50S ribosomal targets), DNA synthesis inhibitors (fluoroquinolones), folic acid synthesis inhibitors, and analgesics (Table S1 ). Using time series of optical density measured directly from a 96-well plate reader, we estimated growth with nonlinear least-squares fitting (Methods, Author contributions: K.W., E.D.S., and P.C. designed research; K.W. and S.N. performed research; K.W. and P.C. analyzed data; and K.W., S.N., E.D.S., and P.C. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: cluzel@mcb.harvard.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1201281109/-/DCSupplemental. Fig. S1 ). We define g 1...N to be the measured growth rate of cells in our experiments exposed to a treatment with N drugs, D 1 , D 2 , ..., D N . All growth rates are normalized by growth rate in the absence of drugs. To understand the relationship between pairwise drug interactions and the net drug interaction between more than two drugs, we first asked whether one can estimate the growth response to three or four drugs using only our experimental measurements of single drug, g i , and two-drug, g ij , growth rates (Fig. 1) .
We model the effect of each drug, D i , using an associated stochastic variable, X i . Specifically, we assume that the measured (normalized) growth rate is equal to the mean (i.e., expectation) value of that random variable, g i =< X i >. Similarly, in the presence of two drugs, i and j, the normalized growth is taken to be g ij =< X i X j > and, in general, the normalized growth in presence of a combination of N drugs, g 1.. .N , equals the mean value <X 1 . . .X N > of the product of the X i s. The relevant experimental observable, growth, is associated with the moments (or joint moments) of the variables X i , not to the stochastic variables themselves. By construction, then, drug interactions are represented as correlations between these abstract variables. In this framework, an absence of correlation between variables X i and X j indicates that the drugs do not interact, and therefore g ij is equal to the product of the independent growth rate g i and g j . In the absence of interactions between the drugs, this statistical model is equivalent to the well-known Bliss independence model (5, 7) in pharmacology.
Drug Interactions Defined as a Mechanism-Independent Statistical
Problem. To characterize the apparent interactions between drugs (i.e., synergies and antagonisms), we introduce a probability density P(x) = P(x 1 , x 2 , . . ., x N ) that describes the joint distribution of these random variables. Unfortunately, this probability distribution P(x) is not directly accessible, although as we will show, it can be estimated using experimental data. Specifically, we wish to estimate the probability density P(x) using only the growth rate data in response to single drugs and drug pairs. We call this estimate P pair (x), because it depends only on the interactions between drug pairs and the effects of the drugs alone. P pair (x) provides a picture of how the two-drug interactions would accumulate if there were no additional drug interactions, such as those requiring the presence of all three or four drugs. Of course, P pair (x) will provide a good approximation to the true P(x) and, ultimately, to experiments only if the effects of higher-order interactions (three-drug, four-drug) are negligible.
To estimate P pair (x) from experiments, we use entropy maximization (10, 11) (Fig. 1) , a well-established statistical technique that guarantees that P pair (x) contains only the information from our one-drug and two-drug data sets (SI Appendix). In this case, the form of the maximum entropy distribution is given by
where subscripts label the components of x, and h and J represent the collection of free parameters determined by the data (SI Appendix, Figs. S2-S6), and Z is the normalization constant (i.e., partition function). It is straightforward to determine the parameters h i and J ij from our measurements of single and pairwise drug effects at each dosage (SI Appendix).
Three-and Four-Drug Interactions Arise from Accumulation of Pairwise Interactions. Using the estimated distribution P pair (x), one can easily calculate the expected growth response to a larger combination of drugs, g 1,. .N =< X 1 X 2 . . .X N >, where brackets represent an average using the distribution P pair (x). This prediction would match experimental results only if the net effects of the drug combination were to arise entirely from the accumulation of pairwise interactions but not from higher drug interactions. To test this framework, we calculated expected growth response to various combinations of N drugs. We focus on the n = 3 and n = 4 cases, which are near the upper limit of current multidrug treatments in clinical settings. We then directly measured bacterial growth in the presence of these drug combinations A B C Fig. 1 . Growth in response to multiple drugs can be predicted from the growth in response to those drugs singly and in pairs using maximum entropy. (A) Schematic axes showing that the normalized growth responses of bacteria to pairs of drugs (g 12 , g 23 , g 13 ) are used to predict the normalized growth response to all three drugs (g 123 ).
We use the three-drug case as an example; but growth in response to any number (N) of drugs can be predicted as long as we know all pairwise responses. (B) We estimate growth in the presence of drugs using nonlinear least-squares fitting to optical density time series. For each drug i, we define a random variable X i whose expectation value is equal to the growth g i . (C) We made predictions by first estimating the maximum entropy distribution, P, using growth rate data from cells exposed to single drugs and drug pairs. The distribution takes an exponential form parameterized by resilience coefficients (h i , blue circles) and drug-drug coupling coefficients (J ij , pink boxes) that characterize the single drug response and the response to pairs of drugs, respectively. The resilience and coupling coefficients are chosen to ensure that the moments, <X i > and <X i X j >, of P pair match the two-drug growth rate data at each drug dosage. After determining the maximum entropy distribution, the N-drug growth response can be predicted by calculating the expectation values of the product X 1 X 2 ...× N . We find that these expectation values are related to the moments <X i > and <X i X j > by simple algebraic expressions (SI Appendix).
and compared them to our expected results using the estimated distribution P pair (x). Notably, the relationship between the Ndrug response and the responses to single drugs and drug pairsa relationship governed by the distribution P pair (x) calculated from entropy maximization-is well described by simple algebraic expressions (12) (SI Appendix, Fig. S7 ). For example, the response to three drugs (g ijk ) is given by
and the response to four drugs (g ijkl ) is given by
These well-known formulas are fully consistent with our numerical maximum entropy predictions and can be derived from the famous Isserlis theorem (12) in the specific case when P pair (x) is a Gaussian distribution. The simple expressions provide a way to predict the effect of a drug combination on growth without using the sophisticated maximum entropy framework. However, the fact that these simple formulas yield predictions identical (Fig.  S7 ) to those from maximum entropy calculations guarantees that they contain no hidden correlations, only correlations from measured pairwise and single drug effects. Fig. 2A shows representative data collected from bacteria exposed to various concentrations of the combination of three antibiotics, erythromycin, doxycycline, and lincomycin. All three drugs inhibit protein synthesis, erythromycin by inhibiting translocation of peptidyl tRNA, doxycycline by disrupting aminoacyl-t-RNA binding to the ribosome, and lincomycin by inhibiting enzymatic activity of peptidyl transferase. We previously found that lincomycin is antagonistic with both doxycycline and erythromycin, whereas the latter two drugs are synergistic (Fig. S2) . However, because the mode of action is similar for the three drugs, it is possible that these mechanisms might interact in a unique way when all three drugs are present (see also SI Appendix, Fig. S8 for drugs with identical modes of action). Therefore, it is not clear whether the overall effect could be predicted solely from the accumulation of the measured pairwise interactions. Interestingly, Fig. 2A demonstrates that the pairwise interactions are indeed sufficient to accurately predict the growth response to the combination of these three protein synthesis inhibitors.
Next, we tested this approach using chloramphenicol, erythromycin, and salicylate. The former two drugs are protein synthesis inhibitors. The binding of chloramphenicol to its ribosomal target has been shown to enhance the ribosomal binding of erythromycin (13) , and it is therefore not surprising that we found chloramphenicol and erythromycin to be synergistic when used together. Salicylate, the active component of the analgesic aspirin, is known to be a potent inducer of a multidrug efflux pump that contributes to E. coli's resistance to chloramphenicol (14) . Consequently, it is also not surprising that chloramphenicol and salicylate are strongly antagonistic. Although interactions between salicylate and erythromycin have not been studied, we found them to be weakly antagonistic. What happens when the three drugs are combined together? A priori, one might expect a novel effect when all three drugs are present. The presence of salicylate decreases the intracellular concentration chloramphenicol, which might then decrease the binding affinity of erythromycin in a manner that depends on the dosages of salicylate and chloramphenicol. However, we find that pairwise interactions again yield accurate predictions of multidrug effects (Fig. 2B) .
We found similar results for three additional three-drug combinations and also for two four-drug combinations. In all experiments, the predictions from the pairwise experiments provide accurate descriptions of the data (Fig. 2C, Figs . S9-S15, and Table S2 ). Interestingly, although most pairs of drugs interact either synergistically or antagonistically, we found that some three-drug combinations, such as doxycycline-erythromycinlincomycin, act almost independently in larger combinations, whereas others, such as chloramphenicol-salicylate-ofloxacin, display extremely strong interactions and deviate significantly from Bliss independence (Fig. S9 ). Using standard model selection techniques (SI Appendix, Fig. S10 ), we verified that the Bliss independence model may be applicable for select drug combinations, but as a whole, the pairwise model (R 2 = 0.90) performs significantly better than the independent model (R 2 = 0.33) for describing the effects of three or four drugs in combination (Figs. S11-S15). In addition to the previous results, which include drug combinations over a large range of drug dosages, we also surveyed various multidrug interactions by performing five combinatorial experiments yielding 93 unique three-drug combinations and a total of 120 unique dosage combinations (SI Appendix, Figs. S16 and S17 and Table S3 ). We included a large range of drug types, including pain relievers, food preservatives, and inhibitors of DNA synthesis, folic acid synthesis, cell wall synthesis, and protein synthesis. Again, the pairwise model (R 2 = 0.95) significantly outperforms the independent model (R 2 = 0.29) and provides an excellent description of the data. Overall, these results suggest that for a wide range of antimicrobial drugs, the net effect of a drug combination is dominated by the accumulation of pairwise drug interactions, independent of the modes of action of the specific drugs involved.
Effects of Three-Drug Combinations in Staphylococcus aureus. Because this approach does not rely on assumptions about molecular mechanisms, it should then be applicable to other bacterial species. As a model system, we used the bacterium Staphylococcus aureus, a common source of clinical infections. S. aureus are Gram-positive bacteria whose response to antibiotics differ substantially from that of E. coli (15) . As for E. coli, we first measured the growth of S. aureus in response to three drugs: tetracycline, kanamycin, and erythromycin. All three drugs inhibit protein synthesis via different mechanisms. We performed the measurements for all drugs alone, and then repeated the measurement for all pairs of drugs.
Using the single drug and pairwise measurements, we then estimated the distribution P pair (x), which allowed us to calculate the expectation of the growth response to the three-drug combination. We tested these predictions by comparing them with direct measurements of S. aureus growth in the presence of all three drugs. Remarkably, Fig. 2D demonstrates that the mechanism-independent framework correctly predicts the experimentally measured growth response to multidrug exposure in S. aureus based solely on the responses to single and drug pairs.
Quantifying the Contribution of Pairwise Interactions to the Multidrug
Response. Overall, these results suggest that the integrated growth response of bacteria to three-drug and four-drug combinations can be directly inferred from the measured interactions between drug pairs. The data and the predictions are in excellent agreement, and the pairwise model performs significantly better than the Bliss independence model according to model selection techniques. However, the maximum entropy framework (16, 17) provides an additional metric that allows us to further quantify exactly how well the pairwise model captures deviations from independence. To do so, we used the maximum entropy distributions P i (i = 1,2,3), which are consistent with the measured effects of all combinations composed of up to i drugs, to calculate the fraction of total correlations, f c , captured by the pairwise hypothesis (Table S4) . Strikingly, this analysis demonstrates that there is very little additional information (∼3%) encapsulated by pure three-drug interactions. The answer to our original question is therefore surprising: the combined effects of these three-drug combinations follow almost entirely from the effects of the drugs alone and in pairs.
How Exactly Do Pairwise Interactions Accumulate? Our results demonstrate that for a large variety of antimicrobial drug combinations, no new apparent chemical interactions arise when three or four drugs are combined together. Instead, the net effect of the drug combination arises from the cumulative effect of the pairwise interactions. Given this drastic simplification, what outcomes are possible when drugs are combined at specific dosages? Surprisingly, there are still numerous ways that pairwise interactions can be combined to yield higher-order drug combinations ( Fig. 3) , even without requiring novel three-drug or fourdrug effects. For example, weak synergistic interactions between drug pairs, such as those between chloramphenicol and erythromycin or erythromycin and trimethoprim, can combine to yield a cumulative effect that is strongly synergistic at particular doses (Fig. 3A) . Conversely, as we saw, with the initial example of chloramphenicol, ofloxacin, and trimethoprim ( Fig. 3B) , that strong pairwise drug-drug interactions can combine to yield a cumulative drug effect weaker than or similar to the strongest pairwise interaction (Fig. 3D ). In the case of salicylate, chloramphenicol, and ofloxacin, which interact antagonistically when used in pairs, the net result is an antagonistic three-drug effect whose magnitude is similar to that of the pure salicylate-ofloxacin interaction (Fig. 3C) . In all cases, the net effect can be predicted using only the response to drug pairs ( Fig. 3 A-F ), illustrating that a wide range of cumulative effects are possible, depending on the dosages of each drug, even in the absence of pure three-drug or four-drug interactions. Overall, these results offer a mechanismindependent framework for predicting the cooperative effect of drug combinations on bacterial growth using only the information from the response to isolated drugs and drug pairs. Cm, chloramphenicol; Dox, doxycycline; Ery, erythromycin; Kan, kanamycin; Linc, lincomycin; Ofl, ofloxacin; Sal, salicylate; Tet, tetracycline; Tmp, trimethoprim.
Discussion
Our experiments reveal that, for many antimicrobial drug combinations, interactions involving exactly three or more drugs do not appreciably contribute to the overall effect of the combination. The results are complementary to detailed mechanistic models because they impose an upper limit on how much mechanistic information is required to predict bacterial growth. Mechanistic and empirical approaches remain essential to characterize the effects of specific drug pairs (18-23). Remarkably, however, our results reveal that additional information is often not required to predict the effects of larger combinations of drugs. Consequently, these findings may provide a powerful strategy for the rational design of candidate therapies using combinations of three or more drugs, even when full mechanistic descriptions are not available. Nevertheless, the approach does have practical limitations. First, the distribution P pair (x) (or equivalently, the single drug and two-drug effects, g i , and g ij ) measured for a particular bacterial strain cannot, in general, be used to predict the multidrug response in a different strain. Using this approach to screen for multidrug combinations to combat drug-resistant mutants, for example, would require measurements of the relevant two-drug effects in each specific strain. Second, it is important to note that we chose maximum entropy as a systematic way to incorporate deviations from Bliss independence without adding spurious statistical structure. However, there may exist other pairwise models that could also be used to estimate the effects of larger drug combinations. Our primary finding is that at least one such pairwise model exists that provides excellent predictive power. Finally, one can design ad hoc examples in which any pairwise model is likely to fail. For example, if one drug were an enzyme that required two substrates, then the combination of the enzyme with both substrates might yield a completely novel three-body interaction that could not be predicted from the pairwise effects. Interestingly, however, we do not find evidence for such strong three-body interactions in any of our experiments.
Previous studies have also used pairwise approximations in other contexts, but the underlying variables represented the dynamics of specific cellular components or other physical entities such as proteins or neurons (24-30). Most notably, a recent study in cancer cells demonstrated that the expression of some proteins in response to combinations of drugs can be predicted from their responses to smaller drug combinations (24). Elucidating the biological connection between these results, at the level of individual proteins, and the integrated responses of entire cells, such as growth, remains an intriguing issue for future work. Unfortunately, fully mechanistic models of the transcriptional, metabolic, and posttranslational networks governing the multidrug response may be intractable, highlighting the need for phenomenological or statistical models to bridge this gap. To circumvent the difficulties associated with building a mechanistic model, we have formulated the problem using a mechanismindependent statistical approach. By using coarse-grained stochastic variables, X i , whose moments <X 1 ..X n > reflect the effects of a combination of N drugs, we have replaced large, intractable mechanistic models with a remarkably small statistical model of interacting drugs. Although the variables do not have a direct microscopic interpretation, they do offer a very powerful tool for inferring the relationship between the N-drug response and the response to drug pairs. Moreover, we find that simple formulas can yield accurate predictions as well, making the approach widely applicable and easy to implement. From a basic science perspective, the picture emerging from our analysis is surprising because it suggests that the chemical complexity underlying the cellular response to drug combinations often does not exceed that of drug pairs. These findings therefore raise the possibility that the multidrug response in bacteria obeys statistical, rather than chemical, laws for combinations larger than two. Finally, because our findings do not depend on details of any specific cellular system, they offer a powerful predictive framework that may be applicable to other bacteria and even to eukaryotes.
Methods
Bacterial Strains. We used the WT BW25113 strain for all experiments on E. coli (Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514) (31). We used the clinically isolated strain Newman for all experiments on S. aureus (32).
Drugs. We prepared all drug solutions from solid stocks (Table S1 lists 
, and to each well we added a given combination of one, two, three, or four drugs. Specifically, we set up a 2D matrix of one-, two-, three-, or four-drug combinations, with the concentration of one or more drugs increasing along each direction of the plate. In the presence of the drugs, we grew the cells for 10-18 h at 30°C, with shaking at 1,000 rpm on four identical vibrating plate shakers. We measured the absorbance at 600 nm (A 600 ) at time intervals dt (dt = 20 min for E. coli, 30 min for S. aureus) using a Wallac Victor-2 1420 Multilabel Counter (Perkin-Elmer) combined with an automated robotic system (Twister II, Caliper Life Sciences) to transfer plates between shakers and the reader.
Growth Rate Calculation. From the time series of A 600 , we determined growth rates by fitting the early exponential phase portion of curves (0.01 < A 600 <0.1) to an exponential function (MATLAB 7.6.0 curve fitting toolbox, Mathworks). We normalized growth rates in the presence of single drugs (g i ) or multiple drugs (g ij , g ijk , g ijkl ) by the growth rate of cells in the absence of drugs. An example growth curve is shown in Fig. S1 . SEs of the fitted growth parameter are used to estimate uncertainty in growth rates.
To minimize the small effects of day-to-day fluctuations in drug efficacy (typically <5%), we generated a standard dose-response curve (and IC 50 value) for each drug by combining all data involving only exposure to that drug. In all subsequent three and four-drug experiments, we remeasured the IC 50 value for each drug and scaled all concentrations to ensure that it agreed with the IC 50 from the standard curve. Single drug (g i ) and pairwise (g ij ) growth rates at a given set of concentrations were then estimated by interpolating, if necessary, between data points measured at nearby concentrations. 
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Example Growth Curve
An example growth curve is shown in Figure S1 . 
Statistical Framework for Drug Combinations
The ultimate goal of our analysis is to establish a predictive relationship between the effects of small drug combinations (1-or 2-drug combinations) and the effects of larger multi-drug combinations. Because mechanistic models for large intracellular networks are often not tractable, we introduce a statistical framework which, by construction, associates drug interactions to correlations between stochastic variables. The model offers one way of establishing testable predictions by first mapping experimental measurements to moments of a joint probability distribution. The problem is then reduced to estimating the unknown distribution, which can be achieved using statistical techniques, such as entropy maximization, or (in principle) by incorporating other assumptions about the underlying physical system. Specifically, we assume that interactions between N drugs can be modeled as correlations between N continuous stochastic variables, X i , (i = 1...N ), such that the observed growth of cells (g 1,2..N ) in the presence of N drugs is given by
where brackets represent an expectation value over an ensemble described by the unknown probability density P (x 1 , x 2 , ...x N ). If the variables X i are uncorrelated, the growth reduces to a product
which is equivalent to Bliss independence, a common phenomenological model used in pharmacology to describe non-interacting drugs [2] . We would like to ask whether pairwise interactions between drugs can be used to predict the effects of larger combinations of drugs. Within the above framework, predicting effects of drug combinations reduces to estimating moments of the unknown distribution P (x 1 , x 2 , ...x N ) using data on interactions between pairs of drugs. Therefore, to test our hypothesis, we must estimate higher-order moments of P (x 1 , x 2 , ...x N ) (the effects of a multi-drug combination) using only the lower order moments (the effects of two-drug combinations). The question, then, is how does one estimate, without mechanistic assumptions or a physical model, the unknown probability distribution P (x 1 , x 2 , ...x N ) given only information about some collection of moments of that distribution,
Entropy maximization offers one method of solving this problem by choosing a distribution consistent with known moments but that does not incorporate additional statistical structure [18, 19, 33] .
In what follows, we restrict ourselves for illustrative purposes to the threedrug case, though the results are easily generalizable to any larger drug combination. To estimate P (x 1 , x 2 , x 3 ), we maximize the entropy, S(P ), subject to the known moment constrains. The entropy, S(P ), is defined (up to an additive constant) as
where q(x 1 , x 2 , x 3 ) is a continuous prior distribution that accounts for an a priori knowledge gleaned from, for example, physical considerations or experience. The maximization amounts to minimizing the Kullback-Leibler divergence [35] between the distributions P and q, subject to constraints on the moments. We choose the interval [a, b] to be finite and take q(x 1 , x 2 , x 3 ) to be a constant, which is equivalent to assuming a uniform prior distribution. We stress that our results do not depend on a specific choice of [a, b], as long as some minimal conditions are met (see below).
To proceed with the estimation of P (x 1 , x 2 , x 3 ), we first measured the growth response to each drug i alone (g i ) and to all pairs of drugs, (g ij ). To predict the effects of a given three-drug combination, for example, we measured g 1 , g 2 , g 3 , g 12 , g 13 , and g 23 . The corresponding constraints on the distribution are simply
We can use Lagrange multipliers (λ 0 , h 1 , h 2 , h 3 , J 12 , J 13 , J 23 ) to maximize the entropy S(P ) subject to these constraints, which leads to
where Z is a constant (related to λ 0 ) that normalizes the distribution. It can be shown that, in general, the entropy of a distribution calculated in this way corresponds to the global maximum, if it exists [19], [33] .
We have labeled the Lagrange multipliers as h i and J ij in accordance with notation commonly used for the well-known Ising model, which takes a similar form [36] . In the context of our drug interaction model, h i encodes the singledrug growth response and J ij encodes information about deviations from Bliss independence for a given drug pair, with J ij > 0 indicating antagonism and J ij < 0 indicating synergy. We call the parameter h i the resilience coefficient and J ij the drug-drug coupling coefficient between the drugs i and j; they characterize the response to single drugs and to pairs of drugs, respectively (Fig.  S2) . Intuitively, the value of the resilience coefficient reflects the cell growth in response to a given concentration of one drug (Fig. S2) . The resilience coefficient decreases with increasing drug concentration. The drug-drug coupling coefficient, J, reflects, for each drug dosage, the nature of interactions taking place between two given drugs (Fig. S2) . For example, when J is zero, there exists no drug-drug coupling and the two drugs act independently. When J is positive, the drug pair is antagonistic and for negative values, the pair is synergistic.
Growth Rate Predictions and Uncertainties
In practice, we calculate the parameters h i and J ij from experimental data using a standard numerical technique that involves minimizing a dual space Lagrangian [37] . The minimization occurs on a convex surface and can be accomplished with any unconstrained optimization algorithm. For each dosage of a given three-or four-drug combination, we performed the optimization 50 times (for 3 drugs) or 25 times (for four drugs) starting from random initial conditions drawn from a uniform distribution on the interval [−0.5, 0.5]. Nonphysical predictions (g < 0, g > 1) occasionally arise from strongly synergistic or strongly antagonistic combinations, and these are set to 0 (no growth) or 1 (maximum growth), respectively. While the minimization should not be prone to errors due to local minima, we find that fits of similar quality can be achieved using a range of parameter values; hence, there is some uncertainty in the location of the true minimum. Taking random initial conditions allows us to estimate this uncertainty and offer more reliable predictions. All predictions represent the mean of these trials. Error bars of the growth predictions in Figure 2 are ±2σ, with σ the standard deviation of the distribution of trials. Standard errors of the mean, which are between 5 and 8 times smaller, could be used instead to give a true estimate of the error associated with each prediction, but they leave the reader without a sense of σ. Uncertainties in the prediction of drug interactions, (Figure 3 ) must incorporate standard errors from single drug measurements (g i ). Therefore, the error bars represent ± 1 standard error of the mean. For distributions of 25 or 50 trials, the standard error associated with the prediction of the first term (g 12..N ) is much smaller than that of the second term (g 1 g 2 ...g N ) . Uncertainties of the drug interaction predictions are therefore dominated by standard errors in the estimates of single drug growth rates g i appearing in the second term.
Choosing the State Space
The calculation of the maximum entropy distribution requires a specific choice of state space, [a, b], for each continuous stochastic variable X i . First, we note that if the boundaries are chosen such that [a, b] = [−∞, ∞] -that is, the variables take values on the real line -a (normalizable) distribution of the form Equation S6 does not exist, because there are no constraints on the variances, X 2 i . In practice, this difficulty can be circumvented by choosing [a, b] to be finite, which puts implicit limits on the variance of each variable. While this amounts to an additional assumption, we find empirically that the predictions of higher moments from lower moments do not depend on the choice [a, b] as long as i) the distribution of the form Equation S6 is normalizable and ii) a solution to Equations S5, S6 can be found for some choice of Lagrange multipliers. The specific values of the Lagrange multipliers will of course depend on the choice of state space, but the relationship between higher moments and lower moments conforms to that given by Issesrlis' theorem in all cases where a suitable solution to Equation 5 is found. We return to this point below.
Figures S3, S4 illustrate the fit of models with different choices of (a, b) to all two-drug and single drug data. We note that these are not predictions, but simply fits to examine whether a solution to Equations S5, S6 can be found. Figure S3 illustrates that choices with (a, b) = (0, b) for b > 0 do not provide an accurate description of many of the measured drug interactions; that is, a valid solution cannot be found. On the other hand, the fit improves significantly when a < 0 and b > 0 ( Figure S4 ). For sufficiently large |b − a|, the fit again becomes poor, likely because of the failure of numerical integration over the increasingly large state space. Hence, for all three-drug calculations, we choose (a, b) = (−3, 4) ( Figure S4, lower left panel) , which provides an excellent fit (R 2 > 0.99) to the pairwise data, indicating that a solution to Equations S5, S6 is achievable. This choice is not unique, and other choices (e.g. (a, b) = (−9, 10)) are possible but must utilize more computational resources to calculate integrals at the same level of accuracy. For similar reasons, we choose a smaller range (a, b) = (−1, 2) for four-drug predictions to allow for faster computation of the numerical integrals. The final predictions do not depend on these choices of state space, but instead only on the measured growth rates for drug pairs and single drugs. The exact same results are also obtained if we choose the variables to be discrete "spin-like" variables, as long as the value of the spin is sufficiently large (e.g. spin = ±4). In the latter case, the integrals become sums that are easily calculated.
Example Maximum Entropy Distributions
We illustrate example (marginal) maximum entropy distributions calculated for the drug combination salicylate, erythromycin, and chloramphenicol in Figures S5 , S6. Figure S5 shows the pairwise, 3 , and single variable, P 1 (x 1 ) ≡ b a P (x 1 , x 2 , x 3 )dx 3 dx 2 , marginal distributions for the three-drug combination at a given dose of each drug. In this figure, the concentration of chloramphenicol is 0, so these distributions describe the effects of salicylate and erythromycin alone (right panels) and in combination (left panel). Similarly, Figure S6 shows the pairwise and single variable marginal distributions for erythromycin and chloramphenicol in the absence of salicylate. Deviations from the uniform distribution ensure that the experimental measurements of pairwise drug interactions (2-body correlations) and single-drug effects (single variable means) are appropriately described by expectation values of P .
Isserlis' Theorem Describes Observed Moment Relationships
Empirically, we find that the moment relationships derived from our experiments are consistent with the well-known Isserlis' formula [38] ,
or in terms of the growth measurements,
Similar expressions hold for higher order moments. For example,
Isserlis' equations were originally proven for jointly distributed Gaussian variables, but they have also been extended to certain classes of non-Gaussian variables [39] . These relationships can be derived from the maximum entropy results using first order perturbation theory when the drug-drug coupling is small compared to the single drug effects; they are exact if the distribution P (x) is Gaussian. The result ( Figure S7 ) is perhaps not surprising, given that the choice of finite [a, b] implicitly constrains the variance of the distributions. Consider, for example, that the same relationship can also be achieved in the following way. Assume that the variables are constrained such that
for some choice of constants σ 2 i > 0. Under these conditions, the maximum entropy distribution for variables defined on the real line is a Gaussian [33] . Therefore, Isserlis' theorem will describe the moment relationships, and the result will not depend on the specific choices of σ 2 i , as long as they are sufficiently large that a distribution satisfying all moment constraints exists.
The success of Equation S8 and, more generally, Isserlis' theorem in predicting the effects of large drug combinations is, in itself, a striking result. It suggests that one could arrive at the same predictions by assuming, at the outset, that the variables X i come from a multi-variate Gaussian distribution. Such a relationship could arise, for example, from the Central Limit Theorem if one could argue that the underlying stochasticity of intracellular networks contributing to the multi-drug response arises from a sum of independent, or nearly independent, stochastic variables. This remains an open question for future work. Nevertheless, in practice, the simplicity of the algebraic expressions given by Isserlis renders the method useful even to those without extensive computational resources or experience.
Drug With Itself
In pharmacology, Bliss independence is well-known to be a poor model for the effects of a two drugs with highly similar mechanisms. In particular, it is often noted that Bliss independence cannot accurately describe an experiment where a drug is divided into two volumes which are then combined (i.e. the "interactions" of a drug with itself). Our results extend Bliss independence to account for interactions between drug pairs, which raises the question of whether the model can more accurately describe the "interaction" of a drug with itself. Applying equation 8 to a such a scenario, we have
where g(x) is the growth in the presence of a drug at a concentration x. One solution to this equation is given by an exponential function, which is a reasonable model for the dose-response curve of many drugs over limited concentration ranges. However, dose-response curves are typically modeled with a Hill function, g(x) = (1 + (x/K) n ) −1 , which is consistent with our single-drug data but is not a solution of equation S10. To explore the usefulness of equation S10 for describing typical Hill-like dose-response relationships, we consider Hill functions with Hill coefficients of n = 1, n = 2, and n = 5 (and K = 1 without loss of generality). We then compare the predictions of equation S10 and the predictions of Bliss independence (given by g(c 1 + c 2 + c 3 ) = g(c 1 )g(c 2 )g(c 3 )) with the true Hill function ( Figure S8 ). The pairwise model significantly improves upon Bliss independence, especially when Hill coefficients are near 1, but it can not perfectly capture steep features of the dose-response curve for larger n and high drug dosages. These results suggest that the model may lose accuracy at high dosages when drug combinations involve drugs with identical mechanisms of action and steep dose-response curves. In practice, we find that dose response curves rarely have n > 2, and furthermore, the method works well even when drugs have similar-but not identical-modes of action (See Dox-Ery-Linc combo in main text, Figure 2 ). Therefore, this theoretical limitation is unlikely to be relevant in most practical situations.
Failure and Success of Bliss Independent Model
While our pairwise model performs significantly better, on the whole, than the Bliss independent model, we found that some combinations of three drugs may nevertheless be appropriately modeled with Bliss independence. Figure S9 compares predictions from Bliss independence (left) with those from the pairwise model (right) for two 3-drug combinations. In the top drug combination (CmOfl-Sal), the pairwise approximation significantly outperforms the independent model. On the other hand, in the lower panels (Dox-Ery-Linc), the results from both models are highly correlated (r ≈ 0.95) and both provide reasonable fits to the data. The latter result is particularly interesting given the strong interactions that take place between doxycycline-lincomycin (strong suppression) and doxycyline-erythromycin (strong synergy) when used in pairs (see Figure 2 ).
Akaike Information Criteria and Model Selection
To statistically compare the pairwise model with the independent model, we use standard model-selection techniques [40] (see Table S1 for results). Specifically, we assume that the experimental errors are independent and Gaussian distributed with unknown variance σ 2 . We confirm approximate normality of residuals in Figure S10 . We then calculate for each model the Akaike Information Criteria, which is given by
where log(L(ĉ|y)) is the log likelihood function, y is the data, c is maximum likelihood estimate of the free parameters of the model (in this case, σ 2 ), and n is the number of free parameters (n = 1 for both models, corresponding to the unknown error variance). The AIC is an estimate of the expectation value of the relative Kullback-Leibler (KL) divergence between the fitted model and the "true mechanism" generating the observed data. The model with the lowest AIC value among a set of models is considered the best model in that it minimizes the KL divergence between the model and statistical mechanism underlying the data. For independent Gaussian errors, AIC reduces (up to an additive constant) to AIC = −N log(σ 2 ) + 2n,
where N is the number of observations andσ 2 is the maximum likelihood estimate of the variance. In practice, we use a small sample estimator of AIC that includes a bias correction term AIC = −2 log(L(ĉ|y)) + 2n + 2n(n + 1)
The differences in AIC values between the pairwise model and the Bliss independent model can be converted to an Akaiki weight in favor of the pairwise model,
where δ ≡ AIC pair − AIC ind . Because exp(−δ/2) is proportional to the likelihood of the pairwise model given the data, the weight w can be interpreted as a measure of the evidence in favor of the pairwise model as the best of the two models.
Predictions of 3-Drug and 4-Drug Effects
Figures S11 -S15 show predictions for three-drug (Figures S11 -S14) and fourdrug ( Figure S15 ) combinations calculated using the maximum entropy distributions (or, equivalently, using Equation S7). Each figure includes heat maps comparing experimental growth to theoretical predictions (left hand side) as well as a direct comparison of predictions vs. experiments.
Combinatorial Experiments Testing 3-Drug Predictions
In addition to exploring the entire space of 3-drug concentrations for the drug combinations listed above, we have also performed combinatorial experiments to test the predictions of our model on a broad range of 3-drug combinations, each at a single dosage. Each combinatorial experiment involves N drugs, each at a single concentration,
In each experiment, we test all N 3 possible 3-drug combinations and compare the experimental results to predictions from our pairwise model. We choose N to be 5, 6, or 7 and performed 5 combinatorial experiments yielding a total of 93 unique 3-drug combinations and 120 unique dosage combinations. Table S3 lists all drug combinations, and the corresponding comparisons between predictions and experiment are shown in Figures S16, S17 (inset, which includes error bars). The pairwise model performs remarkably well (R 2 = 0.95) and significantly outperforms the naive independence model (R 2 = 0.29), which demonstrates the need to account for pairwise interactions.
To estimate the frequency of pure 3-body interactions, we also include a histogram ( Figure S17, main figure) of the statistical deviations from the pairwise predictions. These deviations, which cannot be statistically explained by the pairwise approximation, occur when the 95 percent confidence interval of the difference δ = g exp − g pred , where g exp is the relative growth from experiment and g pred is the predicted relative growth, does not contain 0. The difference between the boundary of this confidence interval and 0 is defined to be the deviation, ∆I 3 (units are relative growth rate); this deviation may arise from pure 3-drug interactions. In 74 of the 120 drug combinations, the deviation is zero (∆I 3 = 0). In the remaining 46 combinations, the deviations (unexplained drug interactions) are very small (mean= 0.034 ± 0.005), with the maximum of ∆I 3,max = 0.12. P (x 1 , x 2 , x 3 )dx 3 dx 2 (right panels), marginal distributions for the three-drug combination salicylate (2 mM), erythromycin (25µg/mL), and chloramphenicol (0µg/mL). Vertical dashed lines indicate averages x i , which correspond to single drug growth rates g i . Drugs are arbitrarily labeled as 1 (salicylate), 2 (erythromycin), and 3 (chloramphenicol). P (x 1 , x 2 , x 3 )dx 3 dx 2 (right panels), marginal distributions for the three-drug combination salicylate (0 mM), erythromycin (25µg/mL), and chloramphenicol (1µg/mL). Vertical dashed lines indicate averages x i , which correspond to single drug growth rates g i . Drugs are arbitrarily labeled as 1 (erythromycin), 2 (chloramphenicol), and 3 (salicylate). [Ofl], [Tmp] Experiment [Cm] [Ofl], [Tmp] [Ofl]
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